Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.70 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.60 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9131293 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL9275367 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL9274175 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL11040881 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL15966133 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL15966143 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL6366898 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL3805871 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL10773804 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB | |
| SCHEMBL278595 | 0.98 | SIGMAR1 (0.73) | SIGMAR1CARM1PRMT6PRMT8MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262166-A | Polyurethane foam-forming compositions | 速的奥公司 | 2021-01-22 | — | — | CN | claimed |
| EP-2038291-B1 | PROCESS FOR THE SYNTHESIS OF IBANDRONATE SODIUM | CIPLA LTD (IN) | 2010-07-14 | — | — | EP | claimed |
| CN-120117949-A | Method for directly preparing tertiary amine compound from aromatic aldehyde, ketone and secondary amine | 湖南大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-112262166-A | Polyurethane foam-forming compositions | 速的奥公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON | 2018-03-29 | — | — | US | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9573942-B2 | HIV inhibiting 5-amido substituted pyrimidines | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-21 | — | — | US | disclosed |
| US-20170017153-A1 | PHOTOSENSITIVE RESIN COMPOSITION, LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD FOR PRODUCING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9315670-B2 | Composition for forming resist underlayer film and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2038291-A2 | PROCESS FOR THE SYNTHESIS OF IBANDRONATE SODIUM | Cipla Limited (IN) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008058722-A1 | REAGENT AND USE THEREOF FOR THE PRODUCTION OF BISPHOSPHONATES | SANDOZ A/S (DK) | 2008-05-22 | — | — | WO | disclosed |
| EP-1923394-A1 | Reagent and use thereof for the production of bisphosphonates | Sandoz A/S (DK) | 2008-05-21 | — | — | EP | disclosed |
| WO-2008035367-A2 | PROCESS FOR THE SYNTHESIS OF IBANDRONATE SODIUM | CIPLA LTD. (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008035367-A2 | PROCESS FOR THE SYNTHESIS OF IBANDRONATE SODIUM | CIPLA LTD. (IN) | 2008-03-27 | — | — | WO | disclosed |
| US-20070072859-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007013097-A1 | IMPROVED PROCESS FOR THE PREPARATION OF IBANDRONATE SODIUM | NATCO PHARMA LIMITED (IN) | 2007-02-01 | — | — | WO | disclosed |
| US-5308735-A | Aromatic-aldehyde resins, improved solubility | NIPPON PAINT CO., LTD. (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0540016-A1 | Photosensitive resin and resin composition for lithographic printing | Nippon Paint Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | SIGMAR1 2750/4885CARM1 4797/4885PRMT6 4487/4885 |
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | STING1, IRF3, CGAS | SIGMAR1 4426/4885CARM1 4197/4885PRMT6 3389/4885 |
| US-20070072859-A1 | Pharmaceutical compounds | ADRB3, HTR3C, SLC6A2 | SIGMAR1 35/4885CARM1 2512/4885PRMT6 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.